78 results
8-K
ALGS
Aligos Therapeutics Inc
31 May 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
”) of the Board of Directors of the Company (the “Board”) be comprised of a minimum of three independent directors.
As previously disclosed, Jack Nielsen … , the Company expects that the applicable end of the cure period will be November 18, 2024. The Company intends to appoint a third independent director
DEFA14A
ALGS
Aligos Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
4:04pm
& Young LLP, as our independent registered public accounting firm for the year ending December 31, 2024;
3. The amendment of our Amended and Restated
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
are elected;
To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Ernst & Young LLP, as the independent registered public … , FOR the ratification of the appointment of Ernst & Young LLP, as the independent registered public accounting firm, as described in Proposal No. 2
S-8
EX-23.2
oqvo7q0h45czlh9h
12 Mar 24
Registration of securities for employees
4:51pm
S-8
jtm8se05cbtlfmf2i
12 Mar 24
Registration of securities for employees
4:51pm
SC TO-I
EX-99
rh5hb8n0 eobj
30 Jan 24
Issuer tender offer statement
7:04am
424B3
0x5e9uti9vnb
28 Nov 23
Prospectus supplement
4:01pm
8-K
EX-4.2
nuh xaxbpb3b
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-10.1
4bdhtlhkf0xdvdicd53
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm